ABN ABN AMRO Bank N.V.
ABN AMRO Bank N.V. provides various banking products and financial services to retail, private, and corporate banking clients in the Netherlands, rest of Europe, the United States, Asia, and internationally. It operates through three segments: Personal & Business Banking, Wealth Management, and Corporate Banking. The company offers fixed deposits; home improvement; mortgage products; investment products; and car, home travel, and legal expenses insurances. It also provides pension savings; asset-based solutions, including working capital solutions, equipment leases, equipment loans and vendor lease services, clearing services, equity brokerage services, payment and credit cards services; and internet and online banking. The company was incorporated in 2009 and is headquartered in Amsterdam, the Netherlands. ABN AMRO Bank N.V. operates as a subsidiary of Stichting Administratiekantoor Continuïteit Abn Amro Bank.…
Industry Peers
Banks - DiversifiedKey Statistics
About ABN AMRO Bank (AMS: ABN)
›
ABN AMRO Bank (AMS: ABN) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Banks - Diversified industry, part of the Financial Services sector, and reports about 23,408 employees.
The shares were at 40.10 EUR on 19 November 2026, up 56.1% over 52 weeks. Its 52-week range is 25.26 EUR to 44.40 EUR: the price is 9.7% below the high and 58.7% above the low.
At a market capitalisation of 32.68B EUR, it trades at 12.5 times trailing earnings and 10.4 times forward earnings. The median trailing P/E of its 20 largest Banks - Diversified peers is 13.1, so ABN is valued in line with them. It pays a dividend yielding 3.43% (it pays out 43% of its earnings), against a median of 2.48% among the dividend payers in that peer group.
ABN AMRO Bank reports return on equity of 8.3%, an operating margin of 41.3% and revenue up 19.6% year over year.
Its debt exceeds its cash by 75.93B EUR, a debt-to-equity ratio of 2.94. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 47.13 EUR is 17.5% above the current price. The next earnings report is expected on 10 February 2027.